Successful Treatment of Antimony-Resistant Visceral Leishmaniasis with Liposomal Amphotericin B (L-AmpB-LRC) in a Child

Karande, Sunil; Boby, K. F. J.; Lahiri, Keya; Jain, Mamta; Kshirsagar, Nilima A; Gokhale, Prafulla C.; Pandya, Sunil K

doi:10.1177/004947559502500209

Cited by 7 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The studies showed that dopamine can be effectively delivered into the brain and its degradation in circulation can be prevented by incorporating it into liposomes. [20]…”

Section: Liposomal and Targeted Drug Delivery Systemmentioning

confidence: 99%

Drug delivery systems: An updated review

Tiwari

Sriwastawa

et al. 2012

Int J Pharma Investig

1,341

642

View full text Add to dashboard Cite

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals. For the treatment of human diseases, nasal and pulmonary routes of drug delivery are gaining increasing importance. These routes provide promising alternatives to parenteral drug delivery particularly for peptide and protein therapeutics. For this purpose, several drug delivery systems have been formulated and are being investigated for nasal and pulmonary delivery. These include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins, among others. Nanoparticles composed of biodegradable polymers show assurance in fulfilling the stringent requirements placed on these delivery systems, such as ability to be transferred into an aerosol, stability against forces generated during aerosolization, biocompatibility, targeting of specific sites or cell populations in the lung, release of the drug in a predetermined manner, and degradation within an acceptable period of time.

show abstract

“…The studies showed that dopamine can be effectively delivered into the brain and its degradation in circulation can be prevented by incorporating it into liposomes. [20]…”

Section: Liposomal and Targeted Drug Delivery Systemmentioning

confidence: 99%

Drug delivery systems: An updated review

Tiwari

Sriwastawa

et al. 2012

Int J Pharma Investig

1,341

642

View full text Add to dashboard Cite

show abstract

“…8,13 Currently, in the treatment of VL, L-AmBL is used in an extended regimen (7 days), requiring a corresponding length of hospitalization with associated costs and a risk of non-compliance. 14 In a recent study, VL patients were treated with 5 or 7.5 mg/kg body weight L-AmBL in a single dose or 10 mg/kg body weight L-AmBL in a 5-mg/kg double dose. At 1-month follow-up, all of the patients showed 100% initial cure.…”

Section: Introductionmentioning

confidence: 99%

Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study

Sundar

Singh

Rai

et al. 2015

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Liposomal amphotericin B is an effective and safe alternative for the treatment of visceral leishmaniasis in the Indian subcontinent. In this study, we used a higher-dose regimen of an indigenously manufactured liposomal amphotericin B (FUNGISOME; L-AmBL), which was intended to improve the efficacy in terms of long-lasting cure rate. Thirty men and thirty women between 12 and 60 years old with parasitologically confirmed visceral leishmaniasis were enrolled in two cohorts of 15 patients each. Subjects in cohort I were administered one dose (10 mg/kg body weight) of L-AmBL intravenously. After the safety at this dose was confirmed in cohort I, patients were recruited in cohort II. They received one infusion of an escalated dose (15 mg/kg body weight). The safety of these two doses was evaluated over a period of 30 days, and efficacy was assessed for initial cure at day 30 and definitive cure at 6 months. FUNGISOME was found to be safe, with an initial cure rate of 100% at day 30 and a definitive cure rate of 93.3% at the 6-month follow-up in both the cohorts.

show abstract